Companies Kala BIO, Inc.
Kala BIO CEO salary & total pay, FY2025: $907K
Kala BIO (KALA) CEO salary, fiscal 2025: Mark Iwicki (Former CEO) was paid a salary of $111,866 and $906,642 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Kala BIO, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Mark Iwicki's complete compensation dossier
A PDF and a CSV sent to your email: Mark Iwicki's pay in every fiscal year Kala BIO, Inc. reported it, line by line, with Mark Iwicki's equity grants and Kala BIO, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $8,342,714FY2023
- $1,491,187FY2024
- $906,642FY2025
CEO total pay was $906,642 in fiscal 2025, down from $1,491,187 in fiscal 2024.
FY2025: salary $111,866 · bonus $0 · stock awards $166,413 · option awards $627,467
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Todd Bazemore | $489,112 | $585,450 | $76,053 | $2,262,211 | $0 | $0 | $64,146 | $3,476,972 |
| Former Interim Chief Executive Officer, President and Chief Operating Officer | ||||||||
| Kim Brazzell | 420,000 | 522,000 | 76,053 | 285,040 | 0 | 0 | 55,081 | 1,358,174 |
| Former Head of Research and Development and Chief Medical Officer | ||||||||
| Mary Reumuth | 438,962 | 475,550 | 76,053 | 285,040 | 0 | 0 | 47,002 | 1,322,608 |
| Former Chief Financial Officer | ||||||||
| Mark Iwicki | 111,866 | 0 | 166,413 | 627,467 | 0 | 0 | 896 | 906,642 |
| Former Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Todd Bazemore | $3,476,972 | $949,550 | $2,943,656 | ↑ +2,527,422 |
| Kim Brazzell | 1,358,174 | 920,687 | 2,923,073 | ↑ +437,487 |
| Mary Reumuth | 1,322,608 | 778,269 | — | ↑ +544,339 |
| Mark Iwicki | 906,642 | 1,491,187 | 8,342,714 | ↓ −584,545 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company uses base salaries to recognize experience, skills, and responsibilities, and performance-based bonuses to motivate employees to achieve annual goals based on strategic, financial, and operating performance objectives. Equity grants are utilized to create a strong link to long-term performance, foster an ownership culture, and align executive interests with stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Kim Brazzell | Option | 38,388 | — | 14.56 | — |
| Kim Brazzell | Option | 12,819 | — | 7 | — |
| Kim Brazzell | Option | 8,475 | — | 7.53 | — |
| Mark Iwicki | RSU | — | 13,903 | — | 7,730 |
| Mark Iwicki | RSU | — | 2,584 | — | 1,437 |
| Mark Iwicki | RSU | — | 52,969 | — | 29,451 |
| Mark Iwicki | RSU | — | 9,534 | — | 5,301 |
| Mark Iwicki | RSU | — | 22,100 | — | 12,288 |
| Mark Iwicki | RSU | — | 2,450 | — | 1,362 |
| Mark Iwicki | Option | 132,394 | 79,437 | 14.56 | — |
| Mark Iwicki | Option | 30,906 | 33,594 | 7 | — |
| Mark Iwicki | Option | 22,802 | 76,698 | 7.53 | — |
| Mark Iwicki | Option | — | 5,450 | 4.3 | — |
| Mary Reumuth | RSU | — | 10,100 | — | 5,616 |
| Mary Reumuth | RSU | — | 3,176 | — | 1,766 |
| Mary Reumuth | RSU | — | 512 | — | 285 |
| Mary Reumuth | RSU | — | 12,051 | — | 6,700 |
| Mary Reumuth | RSU | — | 3,067 | — | 1,705 |
| Mary Reumuth | Option | 30,120 | 18,072 | 14.56 | — |
| Mary Reumuth | Option | 9,823 | 10,677 | 7 | — |
| Mary Reumuth | Option | 10,358 | 34,842 | 7.53 | — |
| Todd Bazemore | RSU | — | 4,268 | — | 2,373 |
| Todd Bazemore | RSU | — | 794 | — | 441 |
| Todd Bazemore | RSU | — | 16,236 | — | 9,027 |
| Todd Bazemore | RSU | — | 4,334 | — | 2,410 |
| Todd Bazemore | Option | 40,582 | 24,349 | 14.56 | — |
| Todd Bazemore | Option | 14,040 | 15,260 | 7 | — |
| Todd Bazemore | Option | 10,358 | 34,842 | 7.53 | — |
| Todd Bazemore | Option | 37,667 | 7,533 | 7.05 | — |
| Todd Bazemore | Option | 15,000 | 165,000 | 11.22 | — |
| Todd Bazemore | RSU | — | 10,100 | — | 5,616 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrew I. KovenIndependent · Not standing for re-election · Departed during FY | $96,298 | $13,115 | $24,628 | — | — | $134,041 |
| Howard B. RosenIndependent · Not standing for re-election · Departed during FY | 75,000 | 10,535 | 19,595 | — | — | 105,130 |
| Mark IwickiEmployee director · Not standing for re-election · Departed during FY | 68,139 | 10,535 | 19,595 | — | — | 98,269 |
| C. Daniel MyersIndependent · Not standing for re-election · Departed during FY | 67,500 | 10,535 | 19,595 | — | — | 97,630 |
| Marjan FaridIndependent · Not standing for re-election · Departed during FY | 67,500 | 10,535 | 19,595 | — | — | 97,630 |
| Gregory D. PerryIndependent · Compensation · Not standing for re-election · Departed during FY | 44,837 | 10,535 | 19,595 | — | — | 74,967 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $419,274 |
| Equity awards (grant-date value) | $65,790 |
| All other compensation | $0 |
| Total cost of the board | $485,064 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Kala BIO as a peer
Companies that benchmark against KALA
2 companies name KALA as a compensation peer
- Evofem Biosciences, Inc.EVFMFY2024
- Passage BIO, Inc.PASGFY2025
Each company listed discloses KALA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named KALA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Kala BIO, Inc. | 2025 | Mark Iwicki | $111,866 | $166,413 | $627,467 | $0 | $906,642 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-01-30 | 9,339,335 | 317,192 | 19,458 | 96.72% | Passed |
| 2024 | 2024-06-11 | 764,305 | 225,459 | 24,240 | 77.22% | Passed |
| 2023 | 2023-06-22 | 498,054 | 57,912 | 15,185 | 89.58% | Passed |
| 2022 | 2022-10-19 | — | — | — | — | — |
| 2021 | 2021-06-17 | — | — | — | — | — |
| 2020 | — | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2020 | — | —a |
| 2026 | 2026-01-30 | 96.72%b |
| 2024 | 2024-06-11 | 77.22%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “5 Proposal 2 - Advisory Vote on Executive Compensation The affirmative vote of the holders of shares of common stock representing a majority of the votes cast by holders of all shares of common stock present in person or represented by proxy at the meeting and voting affirmatively or negatively on Proposal 2 is required for approval of the advisory vote on executive compensation. || Abstentions: Shares that abstain from voting and broker non-votes are not votes cast and will not be counted as votes cast or voting on Proposal 2.”.
c. Approved under the standard stated in the filing — “Accordingly, abstentions and broker non-votes will have no effect on the voting on Proposal 2.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (16 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Todd Bazemore. DEF 14A, filed 2026-09-24. Section “Executive Compensation”. As printed: 3,476,972. View filing ↗
- Section 01, Kim Brazzell. DEF 14A, filed 2026-09-24. Section “Executive Compensation”. As printed: 1,358,174. View filing ↗
- Section 01, Mary Reumuth. DEF 14A, filed 2026-09-24. Section “Executive Compensation”. As printed: 1,322,608. View filing ↗
- Section 01, Mark Iwicki. DEF 14A, filed 2026-09-24. Section “Executive Compensation”. As printed: 906,642. View filing ↗
- Section 08, Andrew I. Koven. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 134,041. View filing ↗
- Section 08, Howard B. Rosen. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 105,130. View filing ↗
- Section 08, Mark Iwicki. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 98,269. View filing ↗
- Section 08, C. Daniel Myers. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 97,630. View filing ↗
- Section 08, Marjan Farid. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 97,630. View filing ↗
- Section 08, Gregory D. Perry. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 74,967. View filing ↗
- Section 06, 2020 vote. Form 8-K, filed 2020-11-05. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-02-02. Item 5.07 · say-on-pay result. As reported: 96.72% (votes for as printed: 9,339,335). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 77.22% (votes for as printed: 764,305). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 419,274 + equity 65,790 + all other 0 = 485,064, summed across the director compensation table rows.
- Kala BIO, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-09-24. CEO total compensation as printed in Kala BIO, Inc.'s own proxy. As printed: 906,642. View filing ↗